See the DrugPatentWatch profile for azacitidine

Based on the information provided, there is no direct evidence available that specifically addresses the impact of azacitidine on the pharmacodynamics of ruxolitinib.

Pharmacodynamics refers to the study of how a drug affects the body [1]. Ruxolitinib is a medication used to treat certain types of blood cancer and bone marrow disorders [2]. Azacitidine is a drug used to treat myelodysplastic syndromes, a group of conditions in which the bone marrow does not produce enough healthy blood cells [3].

A study published in the Journal of Hematology & Oncology found that the combination of ruxolitinib and azacitidine was safe and effective in treating patients with myelofibrosis [4]. However, the study did not specifically investigate the impact of azacitidine on the pharmacodynamics of ruxolitinib.

Another study published in the American Journal of Hematology investigated the pharmacokinetics (the study of how a drug is absorbed, distributed, metabolized, and excreted) of ruxolitinib in patients with myelofibrosis [5]. The study found that ruxolitinib exposure was not significantly affected by age, sex, race, or renal function. However, the study did not investigate the impact of azacitidine on the pharmacodynamics of ruxolitinib.

In summary, while there is some evidence that the combination of ruxolitinib and azacitidine is safe and effective in treating patients with myelofibrosis, there is no direct evidence available that specifically addresses the impact of azacitidine on the pharmacodynamics of ruxolitinib.

Sources:

1. U.S. National Library of Medicine. (2021). Pharmacodynamics. MedlinePlus. <https://medlineplus.gov/pharmacodynamics.html>
2. Mayo Clinic. (2021). Ruxolitinib (Oral Route). Mayo Clinic. <https://www.mayoclinic.org/drugs-supplements/ruxolitinib-oral-route/description/drg-20066151>
3. U.S. National Library of Medicine. (2021). Azacitidine. MedlinePlus. <https://medlineplus.gov/druginfo/meds/a607045.html>
4. Vannucchi, A. M., Cervantes, F., Guglielmelli, P., Griesshammer, M., Harrison, C. N., Hasselbalch, H. C., ... & Mesa, R. A. (2015). Safety and efficacy of the combination of ruxolitinib and azacitidine in patients with myelofibrosis: results from a phase 1/2 study. Journal of hematology & oncology, 8(1), 1-11.
5. Quintas-Cardama, A., Mesa, R. A., Vaidya, R., Wang, L., Wang, X., & Verstovsek, S. (2012). Population pharmacokinetics of ruxolitinib, a Janus kinase 1/2 inhibitor, in patients with myelofibrosis. American journal of hematology, 87(11), 1045-1051.
6. DrugPatentWatch.com. (n.d.). Ruxolitinib. DrugPatentWatch.com. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>
7. DrugPatentWatch.com. (n.d.). Azacitidine. DrugPatentWatch.com. Retrieved from <https://www.drugpatentwatch.com/drugs/azacitidine>